Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Tissue Transplantation01:24

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Matching-adjusted indirect comparison of acoltremon ophthalmic solution 0.003% and cyclosporine 0.05% ophthalmic emulsion for increased tear production in patients with dry eye disease.

Journal of comparative effectiveness research·2026
Same author

Atopic dermatitis and ocular surface disorders: a United States claims-based cross-sectional study.

BMC ophthalmology·2026
Same author

Effect of Cyclosporine Ophthalmic Solution 0.09% on Signs and Symptoms of Dry Eye Disease in Patients Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%: Results from a Single-Arm, Open-Label, Phase 4 Study.

Clinical ophthalmology (Auckland, N.Z.)·2026
Same author

Patient-Reported Symptoms Versus Clinician-Measured Signs to Distinguish Sjogren's in Patients With Dry Eye.

Translational vision science & technology·2026
Same author

Impact of Corneal Punctate Epithelial Staining on Patient Satisfaction After Cataract Surgery: An Area of Unmet Need for Clinical Guidance.

Cornea·2026
Same author

Surgical Considerations for the Human Implantation of the Gore Synthetic Corneal Device.

Cornea·2025

Related Experiment Video

Updated: May 19, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Ocular graft-versus-host disease.

Michelle Hessen1, Esen K Akpek

  • 1Ocular Surface Diseases and Dry Eye Clinic, The Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.

Current Opinion in Allergy and Clinical Immunology
|August 16, 2012
PubMed
Summary
This summary is machine-generated.

Graft-versus-host disease (GVHD) frequently causes ocular surface problems after allogeneic hematopoietic stem cell transplantation. Early diagnosis and treatment are crucial for preserving vision, with topical cyclosporine showing promise.

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

Related Experiment Videos

Last Updated: May 19, 2026

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model
10:29

Induction of Graft-versus-host Disease and In Vivo T Cell Monitoring Using an MHC-matched Murine Model

Published on: August 29, 2012

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

Area of Science:

  • Ophthalmology
  • Hematology
  • Immunology

Background:

  • Allogeneic hematopoietic stem cell transplantation (HSCT) can lead to graft-versus-host disease (GVHD).
  • Ocular surface complications are a significant source of morbidity in patients undergoing HSCT.
  • Chronic GVHD affects a substantial percentage of patients, impacting ocular health.

Purpose of the Study:

  • To determine the frequency and severity of ocular surface involvement in allogeneic HSCT recipients with GVHD.
  • To review and evaluate the clinical outcomes of emerging treatments for ocular GVHD.
  • To understand the impact of GVHD on the ocular surface.

Main Methods:

  • This study is a review of existing literature on ocular surface involvement in GVHD.
  • Analysis of reported frequencies and severities of ocular complications.
  • Evaluation of treatment modalities, including newer therapeutic options.

Main Results:

  • Ocular involvement is reported in 60-90% of chronic GVHD patients.
  • Dry eye is the most common finding (up to 90%), with posterior segment complications in 12.8% post-HSCT.
  • Topical anti-inflammatory agents (corticosteroids, calcineurin inhibitors like cyclosporine, tacrolimus) and antifibrotic agents (tranilast) are used.
  • Topical cyclosporine demonstrates good tolerability and efficacy, with improved outcomes at higher doses.

Conclusions:

  • GVHD is a growing cause of ocular surface disease and potential vision loss due to corneal involvement.
  • Prompt diagnosis and comprehensive treatment (local and systemic) are essential for vision preservation.
  • Aggressive management strategies are key to mitigating visual impairment from ocular GVHD.